Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.70 |
| ▸ | ITGAV | P06756 | 17/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.54 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717622 | 0.98 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL4398060 | 0.98 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL4394126 | 0.95 | ITGB3 (0.64) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL243759 | 0.88 | ITGB3 (0.63) | ITGB3ITGAVITGB5HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL14914649 | 0.87 | ITGB3 (0.61) | ITGB3ITGAVITGB5HDAC3HDAC4 | |
| SCHEMBL10861718 | 0.84 | CYP1A2 (0.66) | ITGB3ITGAV | |
| SCHEMBL30446097 | 0.84 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL8180590 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL18381352 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL2843026 | 0.83 | DRD3 (0.56) | ITGB3ITGAVITGB5ITGB6ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106381092-A | Environment-friendly all-purpose adhesive | 无锡万能胶粘剂有限公司 | 2017-02-08 | — | — | CN | disclosed |
| CN-103524559-B | Ester derivant of polysubstituted 4-methylamino benzenecarboximidamide and its production and use | 西藏海思科药业集团股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105523999-A | Dabigatran etexilate intermediate synthesis method | CHONGQING PHARM RES INST CO | 2016-04-27 | — | — | CN | disclosed |
| WO-2015124764-A1 | SYNTHESIS PROCESS OF DABIGATRAN ETEXILATE MESYLATE, INTERMEDIATES OF THE PROCESS AND NOVEL POLYMORPH OF DABIGATRAN ETEXILATE | ERREGIERRE S.P.A. (IT) | 2015-08-27 | — | — | WO | disclosed |
| CN-103524559-A | Ester derivatives of multi-substituted 4-methylamino-benzamidine as well as preparation method and application of ester derivatives | TIBET HAISCO PHARMACEUTICAL GROUP CO LTD | 2014-01-22 | — | — | CN | disclosed |
| EP-1470258-B1 | COMPOSITION AND ITS USE FOR IMPARTING WATER REPELLENCY TO LEATHER OR FURSKINS, TEXTILES AND OTHER FIBROUS MATERIALS | TFL LEDERTECHNIK GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| CN-103058920-A | Preparation method of 3-(2-pyridineamino)ethyl propionate | SHANGHAI INST TECHNOLOGY | 2013-04-24 | — | — | CN | disclosed |
| CN-103058920-A | Preparation method of 3-(2-pyridineamino)ethyl propionate | SHANGHAI INST TECHNOLOGY | 2013-04-24 | — | — | CN | disclosed |
| EP-2512523-A1 | LABELLED INTEGRIN BINDERS | GE Healthcare UK Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000048996-A2 | β-ALANINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-5952306-A | INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0880511-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| CN-1209063-A | Vitronection receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| EP-0880511-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997026250-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | ITGAV, ITGB6, ITGA2B | ITGB3 5/4885ITGAV 1/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.